scholarly article | Q13442814 |
P50 | author | Allan D. Struthers | Q37841538 |
P2093 | author name string | A L Martin | |
G A Lyles | |||
V Godfrey | |||
P2860 | cites work | Nitric oxide and peroxynitrite in health and disease | Q24645400 |
Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays | Q25939005 | ||
Drospirenone: pharmacology and pharmacokinetics of a unique progestogen | Q28140659 | ||
A comparison of the aldosterone-blocking agents eplerenone and spironolactone | Q28276162 | ||
The regulation and pharmacology of endothelial nitric oxide synthase | Q28290711 | ||
Nitric oxide in septic shock | Q33631375 | ||
Inducible nitric oxide synthase and cardiovascular disease. | Q33869924 | ||
Mineralocorticoid selectivity: molecular and cellular aspects | Q33888900 | ||
Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings | Q33913731 | ||
Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. | Q34347790 | ||
Aldosterone in congestive heart failure | Q34472458 | ||
Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction | Q35100840 | ||
The pharmacology of nitric oxide in the peripheral nervous system of blood vessels | Q35139567 | ||
iNOS-mediated nitric oxide production and its regulation | Q35789162 | ||
The new biology of aldosterone | Q36185968 | ||
Effects of aldosterone on the vasculature | Q36375830 | ||
Regulation of smooth muscle by inducible nitric oxide synthase and NADPH oxidase in vascular proliferative diseases | Q36666637 | ||
Aldosterone and the vascular system | Q37133549 | ||
Glucocorticoid and Mineralocorticoid Cross-Talk with Progesterone Receptor to Induce Focal Adhesion and Growth Inhibition in Breast Cancer Cells | Q40616455 | ||
RU486 (mifepristone): mechanisms of action and clinical uses | Q41360492 | ||
Nifedipine inhibits the induction of nitric oxide synthase by bacterial lipopolysaccharide | Q41558166 | ||
Differential effects of some cell signalling inhibitors upon nitric oxide synthase expression and nuclear factor-kappaB activation induced by lipopolysaccharide in rat aortic smooth muscle cells | Q42472118 | ||
Dexamethasone suppresses iNOS gene expression by inhibiting NF-kappaB in vascular smooth muscle cells | Q43709273 | ||
Amlodipine inhibits pro-inflammatory cytokines and free radical production and inducible nitric oxide synthase expression in lipopolysaccharide/interferon-gamma-stimulated cultured vascular smooth muscle cells | Q44065929 | ||
Aldosterone Inhibits Inducible Nitric Oxide Synthase in Neonatal Rat Cardiomyocytes | Q44405066 | ||
Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis | Q44585210 | ||
Direct and indirect effects of aldosterone on cyclooxygenase-2 and interleukin-6 expression in rat cardiac cells in culture and after myocardial infarction. | Q44814504 | ||
The evolution of aldosterone antagonists | Q44889504 | ||
Expression of inducible nitric oxide synthase in cultured smooth muscle cells from rat mesenteric lymphatic vessels | Q45061549 | ||
Regulation of the expression of inducible nitric oxide synthase | Q45089049 | ||
Inter-strain differences in glucocorticoid and mineralocorticoid effects on macrophage and lymphocyte functions in mice | Q46350892 | ||
Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. | Q46689526 | ||
Glucocorticoid-related signaling effects in vascular smooth muscle cells | Q46696400 | ||
Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells. | Q53856893 | ||
Interleukin-1 beta and tumor necrosis factor-alpha synergistically induce NO synthase in rat vascular smooth muscle cells. | Q54637233 | ||
Guide to Receptors and Channels (GRAC), 4th Edition | Q56639335 | ||
Physical separation of aortic corticoid receptors with type I and type II specificities | Q70090706 | ||
Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta | Q70936080 | ||
Progesterone inhibits arterial smooth muscle cell proliferation | Q73677598 | ||
17Beta-estradiol decreases nitric oxide synthase II synthesis in vascular smooth muscle cells | Q77370926 | ||
Differential inhibitory actions by glucocorticoid and aspirin on cytokine-induced nitric oxide production in vascular smooth muscle cells | Q77370970 | ||
Spironolactone induces apoptosis and inhibits NF-kappaB independent of the mineralocorticoid receptor | Q79273396 | ||
P4510 | describes a project that uses | ImageJ | Q1659584 |
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | aorta | Q101004 |
P304 | page(s) | 2003-2014 | |
P577 | publication date | 2011-12-01 | |
P1433 | published in | British Journal of Pharmacology | Q919631 |
P1476 | title | Effects of aldosterone and related steroids on LPS-induced increased expression of inducible NOS in rat aortic smooth muscle cells | |
P478 | volume | 164 |
Q101578601 | Role of mineralocorticoid receptor antagonists in kidney diseases |
Q54350807 | Spironolactone inhibits production of proinflammatory mediators in response to lipopolysaccharide via inactivation of nuclear factor-κB. |
Search more.